What is the official website of Fresenius Kabi Schweiz ?

The official website of Fresenius Kabi Schweiz is https://www.fresenius-kabi.com/de-ch/.

What is Fresenius Kabi Schweiz's cybersecurity risk score?

Fresenius Kabi Schweiz has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Fresenius Kabi Schweiz experienced?

According to Rankiteo, Fresenius Kabi Schweiz currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Fresenius Kabi Schweiz been affected by any supply chain cyber incidents ?

According to Rankiteo, Fresenius Kabi Schweiz has been affected by a supply chain cyber incident involving Fresenius Kabi USA, with the incident ID FRE1781735374.

Does Fresenius Kabi Schweiz have SOC 2 Type 1 certification ?

According to Rankiteo, Fresenius Kabi Schweiz is not certified under SOC 2 Type 1.

Does Fresenius Kabi Schweiz have SOC 2 Type 2 certification ?

According to Rankiteo, Fresenius Kabi Schweiz does not hold a SOC 2 Type 2 certification.

Does Fresenius Kabi Schweiz comply with GDPR ?

According to Rankiteo, Fresenius Kabi Schweiz is not listed as GDPR compliant.

Does Fresenius Kabi Schweiz have PCI DSS certification ?

According to Rankiteo, Fresenius Kabi Schweiz does not currently maintain PCI DSS compliance.

Does Fresenius Kabi Schweiz comply with HIPAA ?

According to Rankiteo, Fresenius Kabi Schweiz is not compliant with HIPAA regulations.

Does Fresenius Kabi Schweiz have ISO 27001 certification ?

According to Rankiteo,Fresenius Kabi Schweiz is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Fresenius Kabi Schweiz operate in ?

Fresenius Kabi Schweiz operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Fresenius Kabi Schweiz have ?

Fresenius Kabi Schweiz employs approximately 34 people worldwide.

Does Fresenius Kabi Schweiz own any subsidiaries ?

Fresenius Kabi Schweiz presently has no subsidiaries across any sectors.

How many LinkedIn followers does Fresenius Kabi Schweiz have ?

Fresenius Kabi Schweiz's official LinkedIn profile has approximately 975 followers.

What is the NAICS classification code for Fresenius Kabi Schweiz ?

Fresenius Kabi Schweiz is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Fresenius Kabi Schweiz have a Crunchbase profile ?

No, Fresenius Kabi Schweiz does not have a profile on Crunchbase.

Does Fresenius Kabi Schweiz have a LinkedIn profile ?

Yes, Fresenius Kabi Schweiz maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/fresenius-kabi-schweiz.

How many cybersecurity incidents has Fresenius Kabi Schweiz experienced ?

As of July 26, 2026, Rankiteo reports that Fresenius Kabi Schweiz has experienced 3 cybersecurity incidents.

How many peer or competitor companies does Fresenius Kabi Schweiz have ?

Fresenius Kabi Schweiz has an estimated 5,709 peer or competitor companies worldwide.

What types of cybersecurity incidents has Fresenius Kabi Schweiz faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

FKS

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Fresenius Kabi Schweiz Vendor Cyber Rating & Cyber Score

fresenius-kabi.com

Add Your Compliance Badge

Als global tätiges Gesundheitsunternehmen ist Fresenius Kabi «Committed to Life». Unsere Produkte, Technologien und Services werden zur Therapie und Versorgung von kritisch und chronisch kranken Patientinnen und Patienten eingesetzt. Mit mehr als 41'000 Mitarbeitenden in über 100 Ländern bieten wir Zugang zu hochwertigen und lebenswichtigen Arzneimitteln und Technologien. Im Bereich Biopharma entwickeln wir Biosimilars für Autoimmunerkrankungen und die Onkologie. In der Klinischen Ernährung tragen unsere enteralen und parenteralen Produkte entscheidend zur Verbesserung der Nährstoffversorgung von Patientinnen und Patienten bei. Im Bereich MedTech entwickeln und liefern wir hochpräzise Infusionspumpen, innovative Systeme für Zell- und

FKS A.I CyberSecurity Scoring

Scoring History

FKS

Fresenius Kabi Schweiz CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Fresenius Kabi USA

Breach

100

1/2026

Fresenius Kabi ...

FRE1781735374

Fresenius Group

Ransomware

100

5/2020

FRE1770566194

Fresenius Kabi Schw...

Ransomware

05/2020

FRE2038291222

Loading…

A.I.

FKS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for FKS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Schweiz in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Fresenius Kabi Schweiz in 2026.

Incident Types FKS vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Fresenius Kabi Schweiz in 2026.

Incident History - FKS (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Fresenius Kabi Schweiz Subsidiaries

FKS

Pharmaceutical Manufacturing

Website: https://www.fresenius-kabi.com/de-ch/

Company Size: 34

Fresenius KabiPharmaceutical Manufacturing

Fresenius GroupHospitals and Health Care

Fresenius Digital TechnologyInformation Technology & Services

Fresenius Investor RelationsKrankenhäuser und Gesundheitseinrichtungen

Helios Health GmbHHospitals and Health Care

QuirónsaludWellness and Fitness Services

Helios Kliniken GmbHHospitals and Health Care

Fresenius Kabi BrasilPharmaceutical Manufacturing

Fresenius Kabi USAPharmaceutical Manufacturing

Fresenius Kabi FrancePharmaceutical Manufacturing

Fresenius Kabi CanadaPharmaceutical Manufacturing

Fresenius Kabi Asia PacificPharmaceutical Manufacturing

Fresenius Kabi ArgentinaPharmaceutical Manufacturing

Fresenius Kabi EspañaPharmaceutical Manufacturing

Fenwal, Inc., a Fresenius Kabi CompanyMedical Equipment Manufacturing

Fresenius Kabi EcuadorPharmaceutical Manufacturing

Fresenius Kabi MedTech EuropeMedical Equipment Manufacturing

Fresenius Kabi PortugalPharmaceutical Manufacturing

Fresenius Kabi EuropePharmaceutical Manufacturing

Fresenius Kabi ChilePharmaceutical Manufacturing

Fresenius Kabi ColombiaPharmaceutical Manufacturing

Fresenius Kabi UKPharmaceutical Manufacturing

MOTIV eLearningHospitals and Health Care

Fresenius Kabi ItaliaPharmaceutical Manufacturing

Fresenius Kabi AustriaPharmaceutical Manufacturing

Fresenius Kabi Australia and New ZealandPharmaceutical Manufacturing

Fresenius Kabi Business ServicesAccounting

Fresenius Kabi PolskaPharmaceutical Manufacturing

Fresenius Kabi DanmarkPharmaceutical Manufacturing

Fresenius Kabi South AfricaPharmaceutical Manufacturing

Fresenius Kabi NetherlandsPharmaceutical Manufacturing

Fresenius Kabi IrelandPharmaceutical Manufacturing

Fresenius Kabi Viet Nam Pharmaceutical Manufacturing

Fresenius Kabi BelgiumPharmaceutical Manufacturing

Fresenius Kabi (Singapore) Pte Ltd, SingaporePharmaceutical Manufacturing

Fresenius Kabi Puerto RicoManufacturing

Fresenius Kabi MéxicoPharmaceutical Manufacturing

Unidos por la Nutrición Clínica MéxicoHospitals and Health Care

Loading…

Fresenius Kabi Schweiz Similar Companies

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Loading…

NEWS

Fresenius Kabi Schweiz CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 22, 2021 08:00 AM

FDA, CISA Warn of Fresenius Kabi Infusion Pump Flaws

US government authorities have issued an advisory warning about remotely exploitable security vulnerabilities in certain Fresenius Kabi infusion pump systems.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-10681

SUMMARY

In Zephyr's userspace dynamic-objects subsystem, thread_idx_alloc() in kernel/userspace/userspace.c allocated a new thread permission index from the global _thread_idx_map[] bitmap without holding lists_lock. On SMP systems, two user-mode threads invoking the k_object_alloc(K_OBJ_THREAD) syscall concurrently can both observe the same low free bit, perform the same non-atomic RMW to clear it, and return the identical tidx. The two newly created K_OBJ_THREAD objects are then assigned the same thread_id, so the two user threads alias a single bit position in every kernel object's perms[] bitfield: any subsequent grant of access on a kernel object to one thread is implicitly a grant to the other, defeating userspace ACL isolation. A secondary lost-update window between the unlocked &=~BIT() in alloc and the locked |= BIT() in thread_idx_free() can also leak entries from the thread-index pool. The defect is reachable from any user-mode thread via the unrestricted __syscall k_object_alloc and is gated on CONFIG_USERSPACE, CONFIG_DYNAMIC_OBJECTS, and CONFIG_SMP. The flaw was introduced when the per-thread permission index was added in 2018 and is present in every release up to and including v4.4.0. Fixed by holding lists_lock across the bitmap RMW and the permissions clear (and inlining the obj_list traversal that previously took the lock itself).

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:L

Impact Score

5.5

Exploitability

REFERENCES

CVE-2026-66013

SUMMARY

OpenRemote before 1.26.2 contains an authentication bypass vulnerability in the console registration API that allows unauthenticated attackers to update existing console assets by supplying a known asset identifier. Attackers can overwrite push notification tokens and console metadata without authentication or ownership validation, redirecting notifications or denying delivery to legitimate consoles.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-66012

SUMMARY

SiYuan before v3.7.2 contains a missing authorization vulnerability in the POST /mcp kernel endpoint, which is gated only by a general auth check (model.CheckAuth) with no admin-role or read-only enforcement. This exposes 31 MCP tools, including a file tool with list/read/write/delete/rename/copy actions across the entire workspace. When the Publish server is enabled in anonymous mode (Conf.Publish.Enable=true and Conf.Publish.Auth.Enable=false), the Publish reverse proxy attaches an anonymous RoleReader JWT to proxied requests, allowing a remote unauthenticated attacker to reach /mcp. The attacker can read conf/conf.json to extract accessAuthCode, api.token, and cookieKey in plaintext, write arbitrary files in the workspace, and plant a plugin into data/plugins/ that executes with nodeIntegration:true and no contextIsolation on the next desktop launch, leading to administrator takeover.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 10)

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 10.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

CVE-2026-66011

SUMMARY

ImageMagick before 7.1.2-27 contains a memory leak vulnerability in the magick command-line interface when invalid options are provided. Attackers can trigger memory exhaustion by repeatedly supplying malformed command-line arguments to consume system resources.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:L

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.8

REFERENCES

CVE-2026-64529

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: crypto: qat - remove unused character device and IOCTLs The QAT driver exposes a character device (qat_adf_ctl) with IOCTLs for device configuration, start, stop, status query and enumeration. These IOCTLs are not part of any public uAPI header and have no known in-tree or out-of-tree users. Device lifecycle is already managed via sysfs. The ioctl interface also increases the attack surface and is the subject of a number of bug reports. Remove the character device, the IOCTL definitions, and the related data structures (adf_dev_status_info, adf_user_cfg_key_val, adf_user_cfg_section, adf_user_cfg_ctl_data). Drop the now-unused adf_cfg_user.h header and strip adf_ctl_drv.c down to the minimal module_init/module_exit hooks for workqueue, AER, and crypto/compression algorithm registration. Clean up leftover dead code that was only reachable from the removed IOCTL paths: adf_cfg_del_all(), adf_devmgr_verify_id(), adf_devmgr_get_num_dev(), adf_devmgr_get_dev_by_id(), adf_get_vf_real_id() and the unused ADF_CFG macros. Additionally, drop the entry associated to QAT IOCTLs in ioctl-number.rst.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…